Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.290
+0.110 (9.32%)
Nov 4, 2024, 4:00 PM EST - Market closed
Spero Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | 118.46 | 103.78 | 53.51 | 18.26 | 9.33 | 18.15 | Upgrade
|
| Revenue Growth (YoY) | 118.43% | 93.95% | 193.10% | 95.67% | -48.59% | 357.56% | Upgrade
|
| Cost of Revenue | 74.01 | 51.44 | 47.59 | 64.53 | 67 | 65.78 | Upgrade
|
| Gross Profit | 44.45 | 52.34 | 5.92 | -46.27 | -57.67 | -47.63 | Upgrade
|
| Selling, General & Admin | 23.59 | 25.55 | 36.48 | 41.7 | 21.44 | 15.59 | Upgrade
|
| Operating Expenses | 23.59 | 25.55 | 36.48 | 41.7 | 21.44 | 15.59 | Upgrade
|
| Operating Income | 20.86 | 26.79 | -30.57 | -87.97 | -79.11 | -63.22 | Upgrade
|
| Interest Expense | - | - | -2.61 | -1.94 | - | - | Upgrade
|
| Interest & Investment Income | 4.52 | 3.94 | 1.11 | 0.35 | 0.4 | 1.33 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 0.43 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.02 | -0.01 | 0.86 | -0.19 | - | 0.74 | Upgrade
|
| EBT Excluding Unusual Items | 25.36 | 30.71 | -31.2 | -89.76 | -78.28 | -61.15 | Upgrade
|
| Merger & Restructuring Charges | - | - | -11.63 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0 | Upgrade
|
| Asset Writedown | -5.31 | -5.31 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -3.58 | - | - | 0.22 | Upgrade
|
| Pretax Income | 20.05 | 25.4 | -46.42 | -89.76 | -78.28 | -60.93 | Upgrade
|
| Income Tax Expense | 2.6 | 2.6 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 17.46 | 22.81 | -46.42 | -89.76 | -78.28 | -60.93 | Upgrade
|
| Net Income | 17.46 | 22.81 | -46.42 | -89.76 | -78.28 | -60.93 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.55 | - | Upgrade
|
| Net Income to Common | 17.46 | 22.81 | -46.42 | -89.76 | -78.83 | -60.93 | Upgrade
|
| Shares Outstanding (Basic) | 53 | 53 | 38 | 31 | 22 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 54 | 53 | 38 | 31 | 22 | 18 | Upgrade
|
| Shares Change (YoY) | 12.90% | 40.98% | 21.65% | 38.01% | 23.27% | 13.49% | Upgrade
|
| EPS (Basic) | 0.33 | 0.43 | -1.23 | -2.91 | -3.52 | -3.35 | Upgrade
|
| EPS (Diluted) | 0.33 | 0.43 | -1.23 | -2.91 | -3.52 | -3.35 | Upgrade
|
| Free Cash Flow | -14.38 | -33 | -7.73 | -64.35 | -86.03 | -50.33 | Upgrade
|
| Free Cash Flow Per Share | -0.27 | -0.62 | -0.21 | -2.08 | -3.84 | -2.77 | Upgrade
|
| Gross Margin | 37.52% | 50.43% | 11.06% | -253.45% | - | -262.46% | Upgrade
|
| Operating Margin | 17.61% | 25.81% | -57.12% | -481.87% | -847.94% | -348.36% | Upgrade
|
| Profit Margin | 14.74% | 21.98% | -86.74% | -491.65% | -844.90% | -335.73% | Upgrade
|
| Free Cash Flow Margin | -12.14% | -31.79% | -14.45% | -352.47% | -922.07% | -277.37% | Upgrade
|
| EBITDA | 21.01 | 27.15 | -29.7 | -87.33 | -78.35 | -62.47 | Upgrade
|
| EBITDA Margin | 17.73% | 26.16% | -55.50% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.15 | 0.37 | 0.87 | 0.65 | 0.76 | 0.75 | Upgrade
|
| EBIT | 20.86 | 26.79 | -30.57 | -87.97 | -79.11 | -63.22 | Upgrade
|
| EBIT Margin | 17.61% | 25.81% | -57.12% | - | - | - | Upgrade
|
| Effective Tax Rate | 12.96% | 10.23% | - | - | - | - | Upgrade
|
| Revenue as Reported | 118.46 | 103.78 | 53.51 | 18.26 | 9.33 | 18.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.